Literature DB >> 28392572

An apoptosis-independent role of TRAIL in suppressing joint inflammation and inhibiting T-cell activation in inflammatory arthritis.

I-Tsu Chyuan1,2, Hwei-Fang Tsai3,4, Hsiu-Jung Liao5, Chien-Sheng Wu6, Ping-Ning Hsu7,8.   

Abstract

Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) has been implicated in the regulation of inflammation in rheumatoid arthritis (RA), primarily due to its ability to promote apoptosis in synoviocytes and infiltrating lymphocytes. The aim of this study was to investigate the immunomodulatory mechanism and role of TRAIL in inflammatory arthritis. We created an animal model of inflammatory arthritis and demonstrated that TRAIL significantly inhibited joint inflammation and reduced the severity of arthritis. The suppression of joint inflammation was not due to the TRAIL-mediated induction of apoptosis in T cells, macrophages or synovial fibroblasts. In contrast, TRAIL directly inhibited T-cell proliferation and suppressed the production of cytokines, which indicated that TRAIL exerted its anti-inflammatory effects by direct inhibition of T-cell activation. Moreover, TRAIL receptor (TRAIL-R)-knockout mice developed more severe disease, and the protective effects of TRAIL were abolished in the experimental arthritis model in TRAIL-R knockout mice. From these results, we conclude that TRAIL suppresses joint inflammation via an apoptosis-independent pathway and directly inhibits T-cell activation. Our results provide a novel apoptosis-independent, immune regulatory role for TRAIL in suppressing inflammatory arthritis and shed light on the development of effective new therapies for autoimmune inflammatory diseases.

Entities:  

Keywords:  T-cell activation; TRAIL; collagen-induced arthritis

Mesh:

Substances:

Year:  2017        PMID: 28392572      PMCID: PMC6203772          DOI: 10.1038/cmi.2017.2

Source DB:  PubMed          Journal:  Cell Mol Immunol        ISSN: 1672-7681            Impact factor:   11.530


  36 in total

Review 1.  The role of T-lymphocytes and cytokines in rheumatoid arthritis.

Authors:  J S Smolen; M Tohidast-Akrad; A Gal; M Kunaver; G Eberl; P Zenz; A Falus; G Steiner
Journal:  Scand J Rheumatol       Date:  1996       Impact factor: 3.641

2.  Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL.

Authors:  J G Emery; P McDonnell; M B Burke; K C Deen; S Lyn; C Silverman; E Dul; E R Appelbaum; C Eichman; R DiPrinzio; R A Dodds; I E James; M Rosenberg; J C Lee; P R Young
Journal:  J Biol Chem       Date:  1998-06-05       Impact factor: 5.157

3.  Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces rheumatoid arthritis synovial fibroblast proliferation through mitogen-activated protein kinases and phosphatidylinositol 3-kinase/Akt.

Authors:  Jacques Morel; Rachel Audo; Michael Hahne; Bernard Combe
Journal:  J Biol Chem       Date:  2005-01-31       Impact factor: 5.157

4.  Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors.

Authors:  J P Sheridan; S A Marsters; R M Pitti; A Gurney; M Skubatch; D Baldwin; L Ramakrishnan; C L Gray; K Baker; W I Wood; A D Goddard; P Godowski; A Ashkenazi
Journal:  Science       Date:  1997-08-08       Impact factor: 47.728

5.  Effect of tumor necrosis factor-related apoptosis-inducing ligand on the reduction of joint inflammation in experimental rheumatoid arthritis.

Authors:  Cheng-Hao Jin; Su Young Chae; Tae Hyung Kim; Han-Kwang Yang; Eun Young Lee; Yeong Wook Song; Dong-Gyu Jo; Kang Choon Lee
Journal:  J Pharmacol Exp Ther       Date:  2009-11-20       Impact factor: 4.030

6.  Blockade of tumor necrosis factor-related apoptosis-inducing ligand exacerbates type 1 diabetes in NOD mice.

Authors:  Qing-Sheng Mi; Dalam Ly; S-E Lamhamedi-Cherradi; Konstantin V Salojin; Li Zhou; Marsha Grattan; Craig Meagher; Peter Zucker; Youhai H Chen; James Nagle; Dennis Taub; Terry L Delovitch
Journal:  Diabetes       Date:  2003-08       Impact factor: 9.461

7.  Induction of costimulation of human CD4 T cells by tumor necrosis factor-related apoptosis-inducing ligand: possible role in T cell activation in systemic lupus erythematosus.

Authors:  Hwei-Fang Tsai; Jiann-Jyh Lai; Ai-Hsiang Chou; Ting-Fang Wang; Chien-Sheng Wu; Ping-Ning Hsu
Journal:  Arthritis Rheum       Date:  2004-02

Review 8.  Following TRAIL's path in the immune system.

Authors:  Christina Falschlehner; Uta Schaefer; Henning Walczak
Journal:  Immunology       Date:  2009-06       Impact factor: 7.397

9.  Intra-articular injection of recombinant TRAIL induces synovial apoptosis and reduces inflammation in a rabbit knee model of arthritis.

Authors:  Qingping Yao; Dai-Wu Seol; Zhibao Mi; Paul D Robbins
Journal:  Arthritis Res Ther       Date:  2006       Impact factor: 5.156

10.  Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an inhibitor of autoimmune inflammation and cell cycle progression.

Authors:  K Song; Y Chen; R Göke; A Wilmen; C Seidel; A Göke; B Hilliard; Y Chen
Journal:  J Exp Med       Date:  2000-04-03       Impact factor: 14.307

View more
  12 in total

1.  Decreased serum TRAIL is associated with increased mortality in smokers with comorbid emphysema and coronary artery disease.

Authors:  Oluremi Ajala; Yingze Zhang; Aman Gupta; Jessica Bon; Frank Sciurba; Divay Chandra
Journal:  Respir Med       Date:  2018-10-19       Impact factor: 3.415

2.  TRAIL regulates T cell activation and suppresses inflammation in autoimmune diseases.

Authors:  I-Tsu Chyuan; Ping-Ning Hsu
Journal:  Cell Mol Immunol       Date:  2020-03-24       Impact factor: 11.530

Review 3.  The new progress in cancer immunotherapy.

Authors:  Ajmeri Sultana Shimu; Hua-Xing Wei; Qiangsheng Li; Xucai Zheng; Bofeng Li
Journal:  Clin Exp Med       Date:  2022-09-15       Impact factor: 5.057

4.  Association of Epileptic and Nonepileptic Seizures and Changes in Circulating Plasma Proteins Linked to Neuroinflammation.

Authors:  John M Gledhill; Elizabeth J Brand; John R Pollard; Richard D St Clair; Todd M Wallach; Peter B Crino
Journal:  Neurology       Date:  2021-01-25       Impact factor: 9.910

5.  TRAIL-Mediated Suppression of T Cell Receptor Signaling Inhibits T Cell Activation and Inflammation in Experimental Autoimmune Encephalomyelitis.

Authors:  I-Tsu Chyuan; Hwei-Fang Tsai; Chien-Sheng Wu; Chi-Chang Sung; Ping-Ning Hsu
Journal:  Front Immunol       Date:  2018-01-22       Impact factor: 7.561

6.  TRAIL inhibits RANK signaling and suppresses osteoclast activation via inhibiting lipid raft assembly and TRAF6 recruitment.

Authors:  Hsiu-Jung Liao; Hwei-Fang Tsai; Chien-Sheng Wu; I-Tsu Chyuan; Ping-Ning Hsu
Journal:  Cell Death Dis       Date:  2019-01-28       Impact factor: 8.469

Review 7.  NK Cell Dysfunction and Checkpoint Immunotherapy.

Authors:  Jiacheng Bi; Zhigang Tian
Journal:  Front Immunol       Date:  2019-08-21       Impact factor: 7.561

Review 8.  The Role of TRAIL/DRs in the Modulation of Immune Cells and Responses.

Authors:  Duygu Sag; Zeynep Ozge Ayyildiz; Sinem Gunalp; Gerhard Wingender
Journal:  Cancers (Basel)       Date:  2019-09-30       Impact factor: 6.639

Review 9.  Influence of Innate Immunity on Cancer Cell Stemness.

Authors:  Anna Pastò; Francesca Maria Consonni; Antonio Sica
Journal:  Int J Mol Sci       Date:  2020-05-09       Impact factor: 5.923

10.  TRAIL promotes epithelial-to-mesenchymal transition by inducing PD-L1 expression in esophageal squamous cell carcinomas.

Authors:  Huanyu Zhang; Guohui Qin; Chaoqi Zhang; Huiyun Yang; Jinyan Liu; Hongwei Hu; Peng Wu; Shasha Liu; Li Yang; Xinfeng Chen; Xueke Zhao; Lidong Wang; Yi Zhang
Journal:  J Exp Clin Cancer Res       Date:  2021-06-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.